Develops novel therapeutics for respiratory diseases in neonatology and pediatric pulmonology.
Windtree Therapeutics, Inc., a dynamic clinical-stage biopharmaceutical company based in Warrington, Pennsylvania, specializes in developing innovative therapies for acute cardiovascular and pulmonary diseases. Our robust pipeline includes several promising programs aimed at addressing critical medical needs. Istaroxime, a lead candidate, is currently undergoing Phase IIb trials for acute decompensated heart failure and Phase IIa trials for early cardiogenic shock. Additionally, AEROSURF, our aerosolized KL4 surfactant, is in Phase IIb trials for treating respiratory distress syndrome in premature infants. We are also advancing Lyophilized KL4 surfactant through Phase IIa trials for lung injury resulting from COVID-19, alongside Rostafuroxin in Phase IIb trials for genetically associated hypertension.
Collaboration lies at the heart of our strategy. Windtree Therapeutics has partnered with Universita degli Studi di Milano-Bicocca to explore new SERCA2a compounds for chronic and acute heart failure. We also maintain a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of KL4 surfactant products. Additionally, our collaboration with Battelle Memorial Institute focuses on developing our ADS technology for our phase III program, enhancing our capabilities in drug delivery and efficacy.
Founded in 1992 as Discovery Laboratories, Inc., our company rebranded to Windtree Therapeutics, Inc. in April 2016. As a subsidiary of Lee's Pharmaceutical Holdings Limited, we remain committed to pushing the boundaries of biopharmaceutical innovation. With a steadfast dedication to advancing patient care through groundbreaking therapies, Windtree Therapeutics continues to pioneer new treatments that address significant medical challenges globally.